Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

Stock

Common

07/21/2016

07/21/2016

December 19, 2016

December 1	19, 2016										
FORM	ЛД								OMB AF	PROVAL	
	UNITED	STATES			AND EXC 1, D.C. 205		IGE CO	MMISSION	OMB Number:	3235-0287	
Check to if no lor subject Section	nger to STATEM 16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSH SECURITIES							Expires: January 31, 2005 Estimated average burden hours per		
Form 4 Form 5 obligation may con See Inst 1(b).	Filed purons Section 170	(a) of the l	Public U	Itility Hol		pany	Act of 19	Act of 1934, 935 or Section	response	0.5	
(Print or Type	Responses)										
1. Name and YANCOPO	Symbol					5. Relationship of Reporting Person(s) to Issuer					
			PHAR		ΓICALS II	NC		(Check	all applicable)	
(Last)	(First) (Middle)	5. Date of Earnest Transaction below)				X_ Officer (give t low)	below)			
777 OLD S ROAD	SAW MILL RIVE	ER	12/15/2	Day/Year) 2016				President Re	egeneron Labo	ratori	
	(Street)			endment, Donth/Day/Yea	ate Original		Aj	Individual or Join			
TARRYTO	OWN, NY 10591						_	<pre>K_ Form filed by Or _ Form filed by Mo erson</pre>			
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative S	Securit	ies Acquir	ed, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securition on Dispose (Instr. 3, 4	d of (D and 5)))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
a				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	12/15/2016			M <u>(1)</u>	195,079	A	\$ 20.32	697,000	D		
Common Stock	12/15/2016			F(1)	10,429	D	\$ 380.09	686,571	D		
Common Stock	12/15/2016			F(1)	95,223	D	\$ 380.09	591,348	D		

500,000

67,976

Ι

I

\$0

\$0

V 500,000 A

V 500,000 D

G

by GRAT

by Trust

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock

Common Stock 5,676 I By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of 6. Date Exercises on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title an Underlyin (Instr. 3 an	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 20.32	12/15/2016		M(1)	(/	195,079	(2)	12/18/2016	Commo Stock
Non-Qualified Stock Option (right to buy)	\$ 381.92	12/16/2016		A	146,815		<u>(3)</u>	12/16/2026	Commo Stock

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
YANCOPOULOS GEORGE			President				
777 OLD SAW MILL RIVER ROAD	X		Regeneron				
TARRYTOWN, NY 10591			Laboratori				

Signatures

/s/**George D. Yancopoulos

**Signature of Reporting Date
Person

Reporting Owners 2

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- (2) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (3) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.